FN-D regimen
WikiDoc Resources for FN-D regimen |
Articles |
---|
Most recent articles on FN-D regimen Most cited articles on FN-D regimen |
Media |
Powerpoint slides on FN-D regimen |
Evidence Based Medicine |
Clinical Trials |
Ongoing Trials on FN-D regimen at Clinical Trials.gov Clinical Trials on FN-D regimen at Google
|
Guidelines / Policies / Govt |
US National Guidelines Clearinghouse on FN-D regimen
|
Books |
News |
Commentary |
Definitions |
Patient Resources / Community |
Patient resources on FN-D regimen Discussion groups on FN-D regimen Patient Handouts on FN-D regimen Directions to Hospitals Treating FN-D regimen Risk calculators and risk factors for FN-D regimen
|
Healthcare Provider Resources |
Causes & Risk Factors for FN-D regimen |
Continuing Medical Education (CME) |
International |
|
Business |
Experimental / Informatics |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aparna Vuppala, M.B.B.S. [2]
Synonyms and keywords:Fludarabine-Novantrone-Dexamethasone Regimen; FMD Regimen; FND Regimen
Overview
FN-D regimen refers to a regimen consisting of fludarabine, mitoxantrone and dexamethasone used to treat indolent non-Hodgkin's lymphoma and rituximab in combination is used for the treatment of advanced follicular lymphoma[1]
Regimen
FFludarabine NNovantrone (mitoxantrone)
DDexamethasone
Indications
References
- ↑ 1.0 1.1 Vitolo U, Ladetto M, Boccomini C, Baldini L, De Angelis F, Tucci A; et al. (2013). "Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: a phase III randomized study by the Fondazione Italiana Linfomi". J Clin Oncol. 31 (27): 3351–9. doi:10.1200/JCO.2012.44.8290. PMID 23960180.